TWI499591B - 雙環嘧啶化合物 - Google Patents

雙環嘧啶化合物 Download PDF

Info

Publication number
TWI499591B
TWI499591B TW102149122A TW102149122A TWI499591B TW I499591 B TWI499591 B TW I499591B TW 102149122 A TW102149122 A TW 102149122A TW 102149122 A TW102149122 A TW 102149122A TW I499591 B TWI499591 B TW I499591B
Authority
TW
Taiwan
Prior art keywords
dihydro
mmol
ylamino
pyrimidin
indol
Prior art date
Application number
TW102149122A
Other languages
English (en)
Chinese (zh)
Other versions
TW201437209A (zh
Inventor
Lance Allen Pfeifer
Spencer Brian Jones
Thomas James Beauchamp
Yen Dao
Bryan Hurst Norman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TW201437209A publication Critical patent/TW201437209A/zh
Application granted granted Critical
Publication of TWI499591B publication Critical patent/TWI499591B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
TW102149122A 2013-01-11 2013-12-30 雙環嘧啶化合物 TWI499591B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361751363P 2013-01-11 2013-01-11
US201361777201P 2013-03-12 2013-03-12

Publications (2)

Publication Number Publication Date
TW201437209A TW201437209A (zh) 2014-10-01
TWI499591B true TWI499591B (zh) 2015-09-11

Family

ID=50031555

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102149122A TWI499591B (zh) 2013-01-11 2013-12-30 雙環嘧啶化合物

Country Status (13)

Country Link
US (1) US8969555B2 (US20070167479A1-20070719-C00034.png)
EP (1) EP2943494B1 (US20070167479A1-20070719-C00034.png)
JP (1) JP6285461B2 (US20070167479A1-20070719-C00034.png)
KR (1) KR101757997B1 (US20070167479A1-20070719-C00034.png)
CN (1) CN104903327B (US20070167479A1-20070719-C00034.png)
AU (1) AU2014205642B2 (US20070167479A1-20070719-C00034.png)
BR (1) BR112015015812A2 (US20070167479A1-20070719-C00034.png)
CA (1) CA2893253C (US20070167479A1-20070719-C00034.png)
EA (1) EA025106B1 (US20070167479A1-20070719-C00034.png)
ES (1) ES2636248T3 (US20070167479A1-20070719-C00034.png)
MX (1) MX2015008971A (US20070167479A1-20070719-C00034.png)
TW (1) TWI499591B (US20070167479A1-20070719-C00034.png)
WO (1) WO2014110000A1 (US20070167479A1-20070719-C00034.png)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201500356A (zh) * 2013-04-12 2015-01-01 Lilly Co Eli 二氫吡啶并嘧啶化合物
LT3071561T (lt) 2013-11-22 2021-08-25 Sabre Therapeutics Llc Autotaksino inhibitorių junginiai
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
US10632104B2 (en) 2015-05-27 2020-04-28 Sabre Therapeutics Llc Autotaxin inhibitors and uses thereof
EP3302465A1 (en) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
US10961242B2 (en) 2017-05-17 2021-03-30 Legochem Biosciences, Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
JP7274767B2 (ja) * 2018-05-24 2023-05-17 ▲広▼州市恒▲諾▼康医▲薬▼科技有限公司 芳香族複素環式化合物及びその医薬組成物
AU2019308231B2 (en) * 2018-07-16 2022-12-22 The Scripps Research Institute Opioid haptens, conjugates, vaccines, and methods of generating antibodies
WO2020156459A1 (zh) 2019-02-01 2020-08-06 湖北生物医药产业技术研究院有限公司 吡咯并嘧啶衍生物及其用途
BR112022004099A2 (pt) * 2019-09-06 2022-05-31 Wuhan Humanwell Innovative Drug Res And Development Center Limited Company Composto, composição farmacêutica, uso do composto, e, método para o tratamento de uma doença relacionada ao atx
AU2020349516A1 (en) * 2019-09-17 2022-03-17 Bial-R&D Investments, S.A. Substituted imidazole carboxamides and their use in the treatment of medical disorders
CN112778334B (zh) * 2019-11-07 2022-04-15 广州市恒诺康医药科技有限公司 芳杂环化合物、其药物组合物及其应用
WO2021115375A1 (zh) * 2019-12-11 2021-06-17 四川海思科制药有限公司 含氮杂环类自分泌运动因子抑制剂及其组合物和用途
WO2022022569A1 (zh) * 2020-07-28 2022-02-03 武汉人福创新药物研发中心有限公司 含氮杂环化合物的固体形式及其药物组合物和用途
WO2022022570A1 (zh) * 2020-07-28 2022-02-03 武汉人福创新药物研发中心有限公司 含氮杂环化合物的盐及其盐的固体形式、药物组合物和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119504A2 (en) * 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
WO2012085167A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032632A2 (en) 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
JPWO2003104230A1 (ja) 2002-06-07 2005-10-06 協和醗酵工業株式会社 二環性ピリミジン誘導体
DE102004020908A1 (de) * 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
JP5697601B2 (ja) * 2008-12-01 2015-04-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 癌に対するオータキシン阻害剤としての2,5−ジアミノ−置換ピリド[4,3−d]ピリミジン
WO2012009258A2 (en) * 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
CN103201262B (zh) * 2010-08-20 2016-06-01 艾米拉医药股份有限公司 自分泌运动因子抑制剂及其用途
WO2013054185A1 (en) * 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
CN106220572B (zh) * 2011-10-28 2019-12-13 因西必泰克新有限公司 哒嗪衍生物的化合物、用途、组合物和试剂盒及制备方法
TW201520219A (zh) * 2013-03-12 2015-06-01 Lilly Co Eli 咪唑並吡啶化合物
TW201500356A (zh) * 2013-04-12 2015-01-01 Lilly Co Eli 二氫吡啶并嘧啶化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119504A2 (en) * 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
WO2012085167A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators

Also Published As

Publication number Publication date
WO2014110000A1 (en) 2014-07-17
JP2016505010A (ja) 2016-02-18
MX2015008971A (es) 2015-09-28
EP2943494B1 (en) 2017-02-22
JP6285461B2 (ja) 2018-02-28
ES2636248T3 (es) 2017-10-05
EA201591098A1 (ru) 2015-11-30
US8969555B2 (en) 2015-03-03
BR112015015812A2 (pt) 2017-07-11
EA025106B1 (ru) 2016-11-30
KR20150092761A (ko) 2015-08-13
CN104903327A (zh) 2015-09-09
KR101757997B1 (ko) 2017-07-13
EP2943494A1 (en) 2015-11-18
CA2893253A1 (en) 2014-07-17
CN104903327B (zh) 2016-09-07
CA2893253C (en) 2017-11-28
US20140200231A1 (en) 2014-07-17
AU2014205642B2 (en) 2016-02-25
TW201437209A (zh) 2014-10-01
AU2014205642A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
TWI499591B (zh) 雙環嘧啶化合物
JP6133491B2 (ja) ジヒドロピリドピリミジン化合物
JP6611799B2 (ja) 新規化合物
CA2900956C (en) Imidazo pyridine compounds
US9029392B2 (en) Quinoline derivatives as kinase inhibitors
JP2017528504A (ja) 線維性疾患などの治療のためのαvβ6インテグリンアンタゴニストとしてのナフチリジン誘導体
JP2014012729A (ja) 有機化合物
JP2011526295A (ja) 5員および6員複素環化合物
TWI476200B (zh) 吡唑並嘧啶化合物及其充作pde10抑制劑之用途
AU2002248151A1 (en) Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof
EP1347980A1 (en) Compounds specific to adenosine-a1,-a2a, and- a3-receptor and uses thereof
WO2017092413A1 (zh) 一种二氨基嘧啶化合物及包含该化合物的组合物
WO2024051720A1 (zh) 靶向抑制clk2的5-吡啶-1h-吲唑类化合物及其应用
JP7413346B2 (ja) ピロロピラゾール誘導体